Sign In
Buy PYPD
$4.29
-0.0800 (-1.83%)
At Close: Jul 31, 2026
PolyPid Ltd. (NASDAQ:PYPD) Sees Significant Increase in Short Interest
01:27am, Sunday, 02'nd Nov 2025
PolyPid Ltd. (NASDAQ: PYPD - Get Free Report) was the recipient of a large growth in short interest during the month of October. As of October 15th, there was short interest totaling 57,800 shares, a
PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025
08:30am, Wednesday, 29'th Oct 2025
PETACH TIKVA, Israel, Oct. 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced t
PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress
08:45am, Tuesday, 30'th Sep 2025
The Company will present the reported topline results from its phase 3 SHIELD II trial at one of the world's leading surgical conferences The Company will present the reported topline results from its
PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference
08:44am, Wednesday, 17'th Sep 2025
PETACH TIKVA, Israel, Sept. 17, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced
PETACH TIKVA, Israel, Sept. 16, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd.
PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference
08:30am, Wednesday, 03'rd Sep 2025
PETACH TIKVA, Israel, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced
PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference
08:30am, Tuesday, 02'nd Sep 2025
PETACH TIKVA, Israel, Sept. 02, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced
PolyPid Ltd. (PYPD) Q2 2025 Earnings Call Transcript
04:52pm, Wednesday, 13'th Aug 2025
PolyPid Ltd. (NASDAQ:PYPD ) Q2 2025 Earnings Conference Call August 13, 2025 8:30 AM ET Company Participants Dikla Czaczkes Akselbrad - CEO & Director Jonny Missulawin - Chief Financial Officer Ori Wa
PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results
07:30am, Wednesday, 13'th Aug 2025
Positive Phase 3 SHIELD II Trial Results - D-PLEX₁₀₀ successfully met its primary efficacy endpoint and demonstrated 58% reduction in SSI
PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer
08:00am, Tuesday, 12'th Aug 2025
Dr. Tweezer-Zaks Transitions from the Company's Board of Directors to Lead Medical Strategy Following Positive Phase 3 Results and Expanding Pipeline Dr. Tweezer-Zaks Transitions from the Company's Bo
PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025
08:00am, Wednesday, 30'th Jul 2025
PETACH TIKVA, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced th
PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market
08:00am, Tuesday, 15'th Jul 2025
PolyPid's proprietary and clinically validated, prolonged-release drug delivery technology aims to subcutaneously deliver GLP-1 for approximately 60 days, compared to current standard of care of weekl
PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results
07:20pm, Monday, 16'th Jun 2025
PETACH TIKVA, Israel, June 17, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today ann
PESG issues a new briefing following PolyPid's clinical success; Revolutionary 58% Reduction in Surgical Site Infections Positions PolyPid's D-PLEX100 as Potential New Standard of Care in the Future P
PESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention
09:40am, Wednesday, 11'th Jun 2025
PESG issues a new briefing following PolyPid's clinical success; Revolutionary 58% Reduction in Surgical Site Infections Positions PolyPid's D-PLEX100 as Potential New Standard of Care in the Future P
